MK-0616, Placebo to MK-0616
MK-0616-029
Phase 3 small_molecule active
Quick answer
MK-0616, Placebo to MK-0616 for Heterozygous Familial Hypercholesterolemia in pediatric patients is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Heterozygous Familial Hypercholesterolemia in pediatric patients
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active